Approvals & regulatory · first seen 42m ago, updated 42m ago
Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
“With this latest appointment, mifepristone has a new boss but an old problem,” writes Julie F. Kay, founder and CEO of Reproductive Futures.
Summary from STAT News.